Karyopharm Therapeutics (KPTI) Tax Provisions (2017 - 2025)
Karyopharm Therapeutics' (KPTI) quarterly Tax Provisions came in at -$41.3 million in Q4 2025, down 37761.47% YoY from N/an in Q4 2024, and down 121479.41% on a QoQ basis from $34000.0 in Q3 2025.
Karyopharm Therapeutics (KPTI) Tax Provisions (2017 - 2025) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 9 years of Tax Provisions data on file, last reported at -$41.3 million in Q4 2025.
- Quarterly Tax Provisions fell 37761.47% year-over-year to -$41.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$41.2 million (down 72308.77% YoY) and the FY2025 annual result came in at -$41.2 million, down 72308.77% from the prior year.
- Tax Provisions retreated to -$41.3 million in Q4 2025, from $34000.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $149000.0 in Q1 2021 to a low of -$41.3 million in Q4 2025.
- A 5-year average of -$2.0 million and a median of $60500.0 in 2023 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2022 — Tax Provisions soared 185.95% — and 2025, when it sank 37761.47%.
- Tracing KPTI's Tax Provisions over 5 years: stood at -$121000.0 in 2021, then soared by 185.95% to $104000.0 in 2022, then climbed by 25.0% to $130000.0 in 2023, then plunged by 183.85% to -$109000.0 in 2024, then slumped by 37761.47% to -$41.3 million in 2025.
- The last three Tax Provisions figures came in at -$41.3 million (Q4 2025), $34000.0 (Q3 2025), and $40000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -41.27 Mn |
| Sep 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 40,000.00 |
| Mar 31, 2025 | 36,000.00 |
| Dec 31, 2024 | -109,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Jun 30, 2024 | 67,000.00 |
| Mar 31, 2024 | 71,000.00 |
| Dec 31, 2023 | 130,000.00 |
| Sep 30, 2023 | 12,000.00 |
| Jun 30, 2023 | 127,000.00 |
| Mar 31, 2023 | 54,000.00 |
| Dec 31, 2022 | 104,000.00 |
| Sep 30, 2022 | 45,000.00 |
| Jun 30, 2022 | 121,000.00 |
| Mar 31, 2022 | 130,000.00 |
| Dec 31, 2021 | -121,000.00 |
| Sep 30, 2021 | 106,000.00 |
| Jun 30, 2021 | 134,000.00 |
| Mar 31, 2021 | 149,000.00 |